NeoGenomics (NASDAQ:NEO) Given Buy Rating at BTIG Research

Key Points

• BTIG Research reiterated its “Buy” rating on NeoGenomics and maintained a $28 price target, implying 55.64% upside from the prior close. Analysts overall rate the stock “Moderate Buy,” with a consensus target of $19.57.
• NeoGenomics exceeded third-quarter expectations, reporting adjusted EPS of $0.07 versus $0.06 expected and revenue of $209.25 million versus $206.70 million. Revenue rose 11.3% year over year, although the company continued to post negative net margins and return on equity.
• Institutional ownership remains high at 98.5%, with several major investors increasing or initiating positions in the company.

NeoGenomics (NASDAQ:NEO - Get Free Report)'s stock had its "buy" rating reiterated by BTIG Research in a note issued to investors on Thursday, Marketbeat reports. They currently have a $28.00 price target on the medical research company's stock. BTIG Research's target price would suggest a potential upside of 55.64% from the company's previous close.

Other research analysts have also recently issued research reports about the stock. Piper Sandler restated an "overweight" rating on shares of NeoGenomics in a research report on Wednesday, October 7th. Zacks Research downgraded shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 28th. Craig Hallum restated a "buy" rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday, July 29th. TD Cowen reissued a "buy" rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of NeoGenomics in a report on Monday, October 12th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.57.

NeoGenomics Stock Up 4.2%

Shares of NASDAQ NEO opened at $17.99 on Thursday. NeoGenomics has a 1 year low of $7.07 and a 1 year high of $20.15. The firm's 50 day moving average price is $17.64 and its 200 day moving average price is $12.77. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.35 and a current ratio of 3.60. The firm has a market cap of $2.31 billion, a P/E ratio of -44.97 and a beta of 1.79.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $209.25 million for the quarter, compared to the consensus estimate of $206.70 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%. The company's revenue was up 11.3% on a year-over-year basis. During the same period last year, the business posted $0.03 EPS. As a group, sell-side analysts anticipate that NeoGenomics will post -0.09 earnings per share for the current year.

Institutional Investors Weigh In On NeoGenomics

Institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC boosted its stake in NeoGenomics by 26.2% during the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company's stock worth $179,158,000 after acquiring an additional 2,549,545 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of NeoGenomics in the 1st quarter valued at approximately $45,725,000. American Capital Management Inc. acquired a new stake in NeoGenomics in the 2nd quarter valued at about $32,648,000. Dimensional Fund Advisors LP lifted its holdings in NeoGenomics by 9.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company's stock worth $19,842,000 after purchasing an additional 225,588 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of NeoGenomics during the 2nd quarter valued at $10,744,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics News Roundup

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Third-quarter results exceeded expectations. NeoGenomics reported adjusted earnings of $0.07 per share, ahead of the $0.06 consensus estimate, while revenue reached approximately $209.25 million versus expectations of $206.70 million. Revenue increased 11.3% year over year, and earnings more than doubled from $0.03 per share in the prior-year quarter. NeoGenomics Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its 2026 revenue guidance. The company now expects full-year revenue of $807 million to $809 million, signaling confidence in continued testing demand and improving operating performance. The raised outlook was highlighted alongside the quarterly earnings beat. NeoGenomics Raises 2026 Guidance
• Positive Sentiment: The earnings outlook improved despite ongoing profitability challenges. The results reinforce the company’s growth trajectory, although NeoGenomics continues to report a negative net margin and negative return on equity. NeoGenomics Earnings Call Transcript

About NeoGenomics

NeoGenomics, Inc NASDAQ: NEO is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company's services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.